Showing results (61-70 of 78) with videos related to
Sort By:
Pageof 8
Future Oncology (London, England)|September 14, 2019
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trialsJorge E Cortes, Hervé Dombret, Akil Merchant, et al.International Journal of Hematology|October 8, 2017
Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosisKeita Kirito, Shinichiro Okamoto, Kohshi Ohishi, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 10, 2017
BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutationAyae Amemiya, Yoshikazu Ito, Yasunori Ishibashi, et al.Current Medical Research and Opinion|December 12, 2017
Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosisKenji Oritani, Kohshi Ohishi, Shinichiro Okamoto, et al.Leukemia Research|December 15, 2010
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET systemTetsuzo Tauchi, Masahiro Kizaki, Shinichiro Okamoto, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 9, 2016
Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire surveySeiichiro Katagiri, Tetsuzo Tauchi, Yuu Saito, et al.Leukemia Research|March 9, 2019
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinibAaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 14, 2015
[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib]Seiichiro Katagiri, Tetsuzo Tauchi, Tomohiro Umezu, et al.Cancer Science|February 28, 2012
Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 studyKazunori Ohnishi, Chiaki Nakaseko, Jin Takeuchi, et al.American Journal of Hematology|September 13, 2008
Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?Yoshinobu Kanda, Shinichiro Okamoto, Tetsuzo Tauchi, et al.Pageof 8